Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2‐positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway after trastuzumab treatment
For metastatic HER2-positive breast cancer patients with abnormal PAM pathway activation and previous trastuzumab treatment, the combination of inetetamab with sirolimus and chemotherapy is equivalent to the combination of pyrotinib and chemotherapy. Therefore, this regimen could be a treatment option for PAM pathway-activated metastatic HER2-positive breast cancer patients.
Authors
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Xiaoying Sun (ORCID: https://orcid.org/0009-0007-5560-2446)
- Jiuda Zhao
- Jing Sun (ORCID: https://orcid.org/0000-0001-6284-7862)
- Qiao Li (ORCID: https://orcid.org/0000-0002-4547-1266)
- Yehui Shi
- Chenghui Li (ORCID: https://orcid.org/0000-0002-2778-5149)
- Feng Liu
- Mengyuan Wang
- Li Cai
- Dan Lv
Institutions
- Harbin Medical University (CN)
- Chongqing University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Qinghai University Affiliated Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
- Anqing City Hospital (CN)
- Anyang Tumor Hospital (CN)
- Fuyang Second People's Hospital (CN)
- Chongqing Three Gorges University (CN)
Publication Details
- Journal
- Cancer Innovation
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1002/cai2.145
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.85